Insurance and Medicare Coverage for AMD Treatment
Medicare Coverage for AMD Injections
According to Medicare.gov and CMS (2024), Medicare Part B covers anti-VEGF intravitreal injections as physician-administered drugs when medically necessary for wet AMD. Coverage falls under the medical benefit, not the pharmacy (Part D) benefit. This means you need Medicare Part B enrollment to access these treatments. You do not need a Part D prescription drug plan for anti-VEGF injections.
According to Medicare.gov (2025), under Original Medicare Part B, Medicare covers 80 percent of the approved amount after the annual Part B deductible of $257 in 2025. You are responsible for the remaining 20 percent coinsurance for each injection and office visit.
According to CMS Coverage Database (2024), Medicare Part B covers aflibercept, ranibizumab, faricimab, brolucizumab, their FDA-approved biosimilars, and pegcetacoplan for geographic atrophy as physician-administered drugs billable under specific codes. Bevacizumab is also covered when used off-label for wet AMD, as it meets the compendia-based coverage criteria that Medicare uses for off-label drug indications. Your retina specialist bills the drug and the injection administration procedure on the same claim. The office visit, imaging studies such as OCT, and the injection itself may all appear as separate line items on your Medicare statement.
According to Medicare.gov and MediGap.com (2024), patients on Original Medicare with a Medigap (supplemental) policy may have most or all of their 20 percent coinsurance covered, reducing out-of-pocket costs for frequent injections to near zero. Patients without Medigap coverage face the full 20 percent coinsurance, which can be substantial when injections occur every month or two at prices of hundreds to thousands of dollars per dose.
Medicare Advantage Plans
Medicare Advantage (MA) plans must cover everything Original Medicare covers, but they can add restrictions. According to published data (JMCP, 2025), approximately 52 percent of Medicare Advantage plan coverage decisions for anti-VEGF drugs included restrictions beyond the FDA label as of April 2024. These restrictions may include prior authorization requirements and step-therapy protocols that require you to try one medication before your plan will cover another.
Your retina specialist may need to submit a prior authorization request to your Medicare Advantage plan before starting treatment or switching medications. This process involves your doctor documenting your diagnosis, treatment history, and medical necessity. Prior authorization can delay treatment initiation by days to weeks, which is a concern for wet AMD where prompt treatment protects vision. Your doctor's office handles the paperwork, but you should ask about your plan's requirements before your first injection appointment.
Coverage details vary between Medicare Advantage plans. Before starting or changing AMD treatment, ask your retina specialist to verify your specific plan's formulary, prior authorization requirements, and cost-sharing amounts. The billing team at your doctor's office can contact your plan to confirm what you will owe for each injection visit.
Coverage for Geographic Atrophy Treatments
According to AAO EyeNet (2024), Medicare Part B covers pegcetacoplan for geographic atrophy, paying 80 percent of the approved cost. Coverage policies for GA-specific treatments were still evolving through 2024-2025 as payers gained experience with these new drugs. Commercial and Medicare Advantage plans may require prior authorization, and some plans limited coverage duration at first. According to payer policy updates (2025), some commercial payers have removed restrictions that previously capped coverage at 12 months, reflecting growing acceptance of long-term GA treatment.
Insurance plans are still working out coverage for newer treatments such as photobiomodulation. As the FDA authorizes new GA therapies, insurance plans evaluate coverage based on clinical evidence and cost-effectiveness data. Your retina specialist can advise you on the current coverage landscape for any treatment they recommend and help you navigate the appeals process if your insurance initially denies coverage for a recommended therapy.
Some insurance plans require step therapy, meaning you must try a less expensive or preferred medication before the plan covers an alternative. For wet AMD, this might mean starting with bevacizumab before your plan covers a branded anti-VEGF agent. Your retina specialist can document medical necessity for a specific drug if step therapy is not appropriate for your clinical situation.
Cost-Saving Strategies
Bevacizumab costs approximately $50 to $100 per injection, compared to $1,500 or more for branded anti-VEGF agents. Clinical evidence from the CATT trial supports comparable effectiveness for wet AMD. Biosimilars for aflibercept and ranibizumab also offer savings. Your retina specialist can discuss whether a lower-cost option meets your clinical needs while reducing your financial burden.
Manufacturers of branded anti-VEGF medications and complement inhibitors offer patient assistance programs for eligible patients. These programs may cover copays, provide free medication, or connect you with other financial resources. Your retina specialist or their billing staff can help you apply for these programs before or during treatment.
Each injection visit generates charges for the drug itself and the injection administration procedure. Under Medicare Part B, both are covered at 80 percent after your deductible. Your explanation of benefits (EOB) statement shows the approved amount, what Medicare paid, and what you owe. Review your EOBs and contact your plan or doctor's office if charges seem incorrect.
Questions About AMD Treatment Coverage
No. Anti-VEGF injections and complement inhibitor injections for AMD are covered under Medicare Part B as physician-administered drugs. Part D covers medications you pick up at a pharmacy. Your AMD injections are administered in the doctor's office and billed through Part B.
Your retina specialist can submit an appeal or a peer-to-peer review with your insurance plan. Providing clinical documentation, imaging results, and treatment history often resolves coverage denials. If the appeal is unsuccessful, your doctor can recommend an alternative medication that your plan covers while maintaining effective disease management.
Annual costs depend on your medication, injection frequency, and insurance coverage. A patient on Original Medicare receiving monthly bevacizumab injections might pay a few hundred dollars per year in coinsurance. A patient receiving branded injections without Medigap could pay several thousand dollars. Your retina specialist and their billing team can estimate your annual costs based on your specific plan and treatment schedule.
AREDS2 supplements are over-the-counter products and are generally not covered by Medicare or most insurance plans. Some health savings accounts (HSAs) or flexible spending accounts (FSAs) may allow you to use pre-tax dollars for these supplements. Ask your eye doctor which specific AREDS2 formulation to buy, as prices vary between brands.
Yes. Discuss cost concerns with your retina specialist. Bevacizumab and biosimilars offer the same clinical benefit as more expensive branded medications at a fraction of the price. Your doctor can switch you to a lower-cost option if it is clinically appropriate for your disease. Financial sustainability of treatment is a legitimate consideration in medication selection.
Know Your Coverage Before You Start
Verify your insurance coverage, understand your out-of-pocket costs, and ask about financial assistance before starting AMD treatment. Informed planning helps you maintain consistent treatment without unexpected financial barriers.